Valens Pharma Ltd. Reports Top-line Results from Voluntary Phase II Trial
EDMONTON, July 28 /CNW/ - Valens Pharma Ltd. (Valens, formerly known as
"CardioMetabolics Inc."), today announced preliminary results from its
voluntary Phase II "Mini-Metr(*)ics" clinical trial evaluating its proprietary
intravenous formulation of dichloroacetate (DCA i.v.) in high risk, geriatric
patients undergoing open heart surgical procedures. A primary objective of
this exploratory Phase II study was to collect key information to help design
further trials. A secondary objective was to determine if there was evidence
of clinical efficacy for endpoints that included reduced time in the Intensive
Care Unit for this patient group. Evidence of efficacy for those endpoints was
not revealed in this pilot study. However, as expected, the biochemical
benefits of DCA shown in earlier trials, such as lower plasma lactate levels
and lower, more stable levels of glucose, were confirmed among treated
patients.